MetaCap

Attovia Therapeutics (ATTO) vs MeiraGTx (MGTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MeiraGTx is the larger company by market cap ($779.9 million vs $690.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATTO-31.05%MGTX-36.41%
+22%-9%-40%
Aug 5, 20261 yearNov 20, 2026
ATTO-25.14%MGTX-38.94%
+30%-6%-42%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATTO versus MGTX key metrics
MetricATTOMGTX
Share price$15.10$7.98
Market cap$690.26M$779.89M
1-day change-3.08%-1.97%
YTD return—+0.38%
1-year return—+6.97%
5-year return—-55.54%
P/E ratio (TTM)—9.17
EPS (TTM)$-5.53$0.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$81.39M
Revenue growth (YoY)—+144.57%
Net income (latest FY)—$-114.20M
Operating margin—-130.20%
Net margin—-140.31%
52-week high$28.00$15.35
52-week low$12.94$6.62
Distance from 52-week high-46.07%-48.01%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+186.09%+247.74%
Average volume337.27K837.25K
Shares outstanding45.71M97.73M
Employees50386
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Attovia Therapeutics

ATTO stock →

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 50 employees

About MeiraGTx

MGTX stock →

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees

ATTO vs MGTX FAQ

Which is bigger, Attovia Therapeutics or MeiraGTx?

MeiraGTx (MGTX) is larger, with a market capitalization of $779.89M compared with $690.26M for Attovia Therapeutics (ATTO).

Are Attovia Therapeutics and MeiraGTx in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons